ARTICLE | Clinical News
Phase II data for Labopharm's Xopenex
January 9, 2001 8:00 AM UTC
Labopharm (TSE:DDS) said a Phase II trial of its oral sustained release formulation of Xopenex levalbuterol showed that asthma patients receiving the compound experienced significant improvements over...